Imax price target raised to $25 from $22 at Rosenblatt

Rosenblatt analyst Steve Frankel raised the firm’s price target on Imax to $25 from $22 and keeps a Buy rating on the shares after the company reported "strong" Q4 results driven by the global success of "Avatar: The Way of Water" and a sharp recovery of its business in China. With the "Avatar effect" driving an uptick in new screen signings, Imax is "well ahead of where we had modeled Q1," the firm added.